The present invention is directed to compositions, kits, and methods for the treatment of conditions associated with hyperproliferative cellular division, such as cancer, diabetes, pre-diabetes, conditions associated with diabetes or pre-diabetes, immune deficiency disease or disorder, conditions associated with the immune deficiency disease or disorder, Alzheimer's disease and conditions associated with Alzheimer's disease, and/or an autoimmune disease and conditions associated with autoimmune diseases. One aspect provides a composition extracted from a biological fluid, such as plasma, from an animal inoculated with an antigenic agent, such as an Ascomyceta (e.g., Aspergillus). One aspect provides for a method of producing such composition. One aspect provides a method for treating conditions associated with hyperproliferative cellular division, diabetes, pre-diabetes, conditions associated with diabetes or pre-diabetes, immune deficiency disease or disorder, or conditions associated with immune deficiency disease or disorder, Alzheimer's disease or conditions associated with Alzheimer's disease, or an autoimmune disease or conditions associated with autoimmune diseases, by administering such a composition to a subject in need thereof.

The present invention is directed to compositions, kits, and methods for the treatment of conditions associated with hyperproliferative cellular division, such as cancer, diabetes, pre-diabetes, conditions associated with diabetes or pre-diabetes, immune deficiency disease or disorder, conditions associated with the immune deficiency disease or disorder, Alzheimer's disease and conditions associated with Alzheimer's disease, and/or an autoimmune disease and conditions associated with autoimmune diseases. One aspect provides a composition extracted from a biological fluid, such as plasma, from an animal inoculated with an antigenic agent, such as an Ascomyceta (e.g., Aspergillus). One aspect provides for a method of producing such composition. One aspect provides a method for treating conditions associated with hyperproliferative cellular division, diabetes, pre-diabetes, conditions associated with diabetes or pre-diabetes, immune deficiency disease or disorder, or conditions associated with immune deficiency disease or disorder, Alzheimer's disease or conditions associated with Alzheimer's disease, or an autoimmune disease or conditions associated with autoimmune diseases, by administering such a composition to a subject in need thereof.

Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.

Provided herein are endothelin receptor antagonistic lasso peptides and related compositions and methods for the management, prevention and/or treatment of an endothelin B receptor (ETBR)-mediated proliferative disease, such as cancer. Biosynthetic methods for producing the lasso peptides are also provided. In some embodiments, the method comprises administering to the subject a therapeutic effective amount of a lasso peptide, wherein the lasso peptide comprises an amino acid sequence selected from SEQ ID NOS:1-17 and 42-56. In particular embodiments, the lasso peptide is GI-D9 cyclized.

The present disclosure is directed to peptide immunogen constructs targeting portions of Pituitary adenylate cyclase-activating polypeptide (PACAP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 20 amino acids and contain (a) a B cell epitope having about more than about 9 contiguous amino acid residues from the PACAP receptor binding or activation regions of the full-length PACAP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed PACAP peptide immunogen constructs stimulate the generation of highly specific antibodies directed PACAP for the prevention and/or treatment of migraine.

The invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) a tetanus toxoid and (c) a diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The invention also provides compositions for use in a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.

The invention relates to the use of an immunologically reactive microbial transglutaminase or its immunologically reactive parts or analogues, which are present in a complex with gliadin or its immunologically reactive parts or analogues, for the diagnosis and/or therapy control of coeliac disease or sprue as well as gluten sensitivity, and a kit for determining the diagnosis and/or therapy control of coeliac disease or sprue as well as of gluten sensitivity, by means of the previously mentioned complex.

The invention relates to the use of an immunologically reactive microbial transglutaminase or its immunologically reactive parts or analogues, which are present in a complex with gliadin or its immunologically reactive parts or analogues, for the diagnosis and/or therapy control of coeliac disease or sprue as well as gluten sensitivity, and a kit for determining the diagnosis and/or therapy control of coeliac disease or sprue as well as of gluten sensitivity, by means of the previously mentioned complex.

Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4.sup.+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.

Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4.sup.+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.